Gameto lands ARPA-H funding to combat menopause with cell therapy

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Company to receive $10m for menopause-targeting therapies based on cell engineering platform developed in collaboration with George Church.

Women’s health biotech Gameto has been selected by the US Government’s Advanced Research Projects Agency for Health (ARPA-H) initiative to be part of its Sprint for Women’s Health initiative. The company will receive $10 million over the next two years to further develop its therapeutic development program for menopause, Ameno.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2174

Gameto

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Gameto is a clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health using proprietary cell engineering technology. The company creates engineered ovarian support cells derived from induced pluripotent stem cells to enable egg maturation outside the body, substantially reducing the duration and hormonal burden of traditional in vitro fertilization protocols. Gameto's platform addresses multiple conditions affecting women's reproductive health, including infertility, menopause, and ovarian disease. The company's lead program, Fertilo, is currently in Phase 3 clinical trials in the United States and has facilitated multiple healthy births in countries where it has received regulatory approval.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE